Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Danone Join SMi's "Allergy Interview Series" Alongside MHRA, Nestle and Nippon Medical SchoolSMi Group Release Exclusive New Interview with Danone Nutricia Research in the Run-Up to their Keynote Address at Allergies 2016
By: SMi Group 
An Interview with Danone Now just with just over 2 weeks to go, SMi Group are thrilled to release the latest addition to the series of Allergy Q&A's with Karen Knipping, Senior Scientist from the immunity platform at Danone Nutricia Research. With over 15 years of experience, Karen Knipping began her career at the Dutch National Institute for Public Health (RIVM), Bilthoven, where she evaluated existing and developed new vaccines for the national immunization program of The Netherlands. In 2001 she started working at Numico Research in Wageningen where she studied anti-allergic and antiviral properties of nutritional compounds. She currently holds a position as a scientist in the immunity platform of Nutricia Research, Utrecht, where she focusses on identifying biomarkers for allergy and other immune related disorders. Her keynote presentation at Allergies 2016, will compare biomarkers for various types of allergies, as well as explore the role of IgE and lg-flC in allergic diseases. When asked about what attendees will take away from her talk, she said: "Upon completion of my presentation the attendees will have a better understanding of the pros and cons of the biomarkers we currently use to diagnose allergy, their predictive value for disease severity and/or response to treatment and the need to invest in the discovery of new and more specific biomarkers." On the biggest challenges in the treatment of allergies, Karen commented: "The biggest challenge is the management of the extreme allergic infants with multiple (food) allergies that sometimes completely have to rely on amino acid based formulas. However, increasing evidence show that generic modulation (e.g prebiotics, probiotics, PUFA's) of the immune system early in life can help in the prevention of allergy. This generic modulation might also help during immunotherapy to obtain sustainable tolerance. Looking at the future, there is an increasing interest in exploring concepts of modulated allergens (e.g. baked milk), tolerogenic peptides or even whole proteins as has been studied with peanut in the LEAP study, and the role of the microbiotia in allergy." The full interview is available to read in the event download centre at: http://www.smi- Further interviews are also available to read with the MHRA, leading allergist Prof. Kimihiro Okubo from Nippon Medical School and Nestle Research Centre. Featured Speakers at Allergies 2016 will include: • Dr Carl Dolman, Immunoglobulins and Allergen Study, Director, NIBSC, MHRA • Dr Thierry Batard, Senior Dir. Innovation & Technological Platforms, Stallergenes Greer • Dr Dirk-Jan Opstelten, R&D Director, HAL Allergy • Dr Mario Scuri, Head of Respiratory, Chiesi Pharmaceuticals • Prof Tim Higenbottam, R&D Director, Allergy Therapeutics Ltd • Dr Sophie Nutten, Group Leader of the Allergy Group, Nestle Research Centre • Dr Anne Marie Salapatek, President and CSO, Inflamax Research • Prof. Moises A. Calderon, Imperial College London A detailed agenda and full speaker line-up is available online at http://www.smi- 3rd Annual Allergies Conference 6th & 7th July 2016 Holiday Inn Kensington Forum, London UK http://www.smi- Sponsored by: Allergy Therapeutics, DBV Technologies, Indoor Biotechnologies and Inflamax Research --- end --- About SMi Group Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
| |||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number